Tyra Biosciences (TYRA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, to be held virtually for stockholders of record as of April 2, 2026.
Meeting materials include the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K.
Voting matters and shareholder proposals
Election of three Class II directors for a three-year term expiring at the 2029 annual meeting: Habib J. Dable, Susan Moran, and Robert More.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Other business may be transacted as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends a vote in favor of both director election and auditor ratification proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Tyra Biosciences
- Q2 net loss rose to $45.6M as R&D spending increased; cash runway extends into 2H 2028.TYRA
Q2 2026 - Oral FGFR3 inhibitor targets blockbuster indications with pivotal data and rapid market entry ahead.TYRA
TD Cowen 46th Annual Health Care Conference - Selective FGFR3 inhibitor advances in key trials, with pivotal data and strong adoption expected next year.TYRA
Jefferies London Healthcare Conference 2025 - Dabogratinib advances in three FGFR3-driven indications, with pivotal data readouts ahead.TYRA
Jefferies Global Healthcare Conference 2026 - August data update aims for 70%+ CR in NMIBC, with rapid expansion into UTUC and large market potential.TYRA
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Dabogratinib targets major FGFR3-driven diseases with pivotal data and market disruption ahead.TYRA
Bank of America Global Healthcare Conference 2026 - Q1 2026 net loss was $39.3M; $147.9M raised, funding operations into H2 2028.TYRA
Q1 2026 - Shareholders will elect directors, ratify the auditor, and review executive pay and governance.TYRA
Proxy filing - Focused on three pivotal clinical programs with robust cash runway and key data readouts in 2026.TYRA
Q4 2025